SoftBank dragged into red by falling Vision Fund valuations, BFSI News, ET BFSI

[ad_1]

Read More/Less


SoftBank Group Corp reported a 397 billion yen ($3.5 billion) net loss for the July-September quarter, dragged down by a $10 billion investment loss at its Vision Fund unit as tech valuations fell.

While CEO Masayoshi Son describes SoftBank as a goose laying “golden eggs”, referring to its stakes in startups that go to market, initial public offerings (IPOs) have dropped off and shares in many top assets like online retailer Coupang fell during the quarter.

“The strategy of let’s create the perception of enhanced value by taking things public hasn’t really worked this year,” Redex Research analyst Kirk Boodry said.

Depressed valuations in SoftBank’s China portfolio amid a regulatory crackdown continued to drag with its stake in ride-hailer Didi, acquired for $12 billion, currently valued at $7.5 billion.

The group’s largest asset, Chinese e-commerce firm Alibaba, fell by around a third in the second quarter.

SoftBank’s quarterly net loss compared with a profit of 628 billion yen in the same period a year earlier.

Bright spots for the Vision Fund include its India portfolio with ride-hailer Ola and logistics firm Delhivery targeting listings.

SoftBank has been trimming stakes following the expiry of lock-up periods, while focusing on investing through its second Vision Fund that has $40 billion in committed capital from SoftBank itself.

SoftBank shares, which have lost around a quarter this year, closed down 0.77% at 6,161 yen ahead of earnings on Monday.

($1 = 113.3500 yen)



[ad_2]

CLICK HERE TO APPLY

2 Stocks To Buy From Motilal Oswal For Gains Of 21% to 29%

[ad_1]

Read More/Less


Buy State Bank of India

Current market price Rs 523
Target price Rs 675
Gains 29.00%

State Bank of India reported a steady quarter, with net earnings growing 67% YoY to Rs 76.3 billion (15% beat), aided by controlled provisions, as asset quality showed remarkable strength, despite the impact of the second COVID wave.

“It created a family pension provision of Rs 74.2 billion, instead of amortizing it over five years, thus prudently deploying one-off gains from the DHFL recovery and tax refund. The bank has fully provided for its exposure towards the SREI group,” the brokerage has said.

The bank saw NPA/NNPA ratios improving by 42bp/25bp QoQ to 4.9%/1.5% as fresh slippage subsided to Rs 41.8 billion (66bp annualized). Restructured book remained in check at 1.2% of loans, while the SMA pool declined sharply to Rs 66.9 billion (27bp of loans).

State Bank of India: Buy for a price target of Rs 675

State Bank of India: Buy for a price target of Rs 675

State Bank of India has reported a robust performance as it bravely fought off the COVID-19 impact and displayed remarkable resilience in asset quality performance.

“The bank has been reporting continued traction in earnings, led by controlled provisions. However, business trends remain modest, impacted by continued deleveraging by corporates. The bank has been able to maintain a strong control on restructured assets at 1.2% of loans, while the SMA pool has declined sharply,” the brokerage has said.

Current market price Rs 710
Target price Rs 860
Gains 21.00%

Motilal Oswal sees a potential upside of almost 21% on the stock of Bharti Airtel from the current levels.

According to Motilal Oswal, the management is making the right noise in terms of steady market share gains, premiumization, cross selling through digital initiatives, and healthy inroads in non-Mobile revenue streams like payments bank, Home, and Enterprise segments. It expects 20% consolidated EBITDA CAGR over FY21-23E, along with tariff/consolidation to drive FCF/deleveraging.

“Bharti’s superior execution quality is reflected in its strong performance in the last 8-10 quarters; 25% YoY growth in consolidated EBITDA, despite no tariff

hikes; and consistent subscriber and revenue market share gains,” the brokerage has said.

Buy Bharti Airtel with a price target of Rs 875

Buy Bharti Airtel with a price target of Rs 875

Motilal Oswal sees a potential for a re-rating in both the India and Africa businesses on the back of steady earnings growth.

“We value Bharti Airtel on a Sep’22E basis, assigning an EV/EBITDA of 11x/5x to the India Mobile/Africa business, arriving at an SoTP-based target price of Rs 860. Our estimates do not factor in any upside from a tariff hike or steep market share gains from VIL’s financial stress. We maintain our Buy rating,” the brokerage has said.

Disclaimer

Disclaimer

The above stock has been picked from the brokerage report of Motilal Oswal. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution. Greynium Information Technologies, the author, and the brokerage house are not liable for any losses caused as a result of decisions based on the article.



[ad_2]

CLICK HERE TO APPLY

1 Financial, 1 Healthcare Stocks To “BUY” As Recommended By Motilal Oswal

[ad_1]

Read More/Less


Buy Divi’s Laboratories at a target price of Rs 6,050

The brokerage believes the stock of Divi’s Laboratories may appreciate up to a target price of Rs 6,050 from current levels, and forecasts gains of +16 percent. The stock was recommended at Rs 5,205 by the brokerage, but it is today trading at Rs 4,812. According to the brokerage, DIVI’s revenue grew 14% YoY to INR19.9b (est. INR20.4b), and the gross margin remained flat YoY at 67.1%. EBITDA margin contracted by 180bp YoY to 41.5% (est. 42.7%) due to higher other expenses/employee costs (up 150bp/30bp as a percentage of sales).

“DIVI’s EBITDA rose 9% YoY to INR8.3b (est. INR8.7b) and PAT grew at a higher rate (15% YoY) to INR6.1b (est. INR6b) due to a lower tax rate of 20.2% in 2QFY22 (v/s 25.1% in 2QFY21)” said the brokerage. According to the research report of Motilal Oswal “inventories of DIVI’s stood at INR 26.8b at the end of 1HFY22 v/s INR17b/INR21.5b at the end of 1H/FY21.”

According to Motilal Oswal, the management stated that “DIVI has recorded some sales of Molnupiravir in 2QFY22. The management said it may not incur further CAPEX on this product in the near term as it has built sufficient capacity to cater to upcoming demand for this drug. The company has started manufacturing Molnupiravir API across all three production lines. The Generics-to-CS sales split stood at 46:54 in 1HFY22. Sales of Nutraceuticals stood at INR1.6b/INR3.1b in 2Q/1HFY22.”

“We reduce our FY22E/FY23E EPS estimate by 5%/2% to reflect some slowdown in offtake related to the Generics segment and higher operational costs”, said the brokerage. Motilal Oswal has said, “We expect a 34% earnings CAGR over FY21-23E, led by increased business prospects from CS and Generics, benefits from Molnupiravir supply to the innovator, improved growth in Nutraceuticals, new product additions in the Generics segment, as well as ~240bp margin expansion on process and productivity improvements.” The broking house has also reported that “Our TP stands at INR6,050 based on 36x 12-month forward earnings. We remain positive on DIVI on the back of strong demand in the CS segment, reduced cost of production due to backward integration, and the Kakinada project being back on track. We reiterate our Buy rating.”

Buy IndusInd Bank at a target price of Rs 1400

Buy IndusInd Bank at a target price of Rs 1400

The brokerage expects IndusInd Bank’s shares to rise to a target price of Rs 1400 from current levels, implying gains of 18 percent. The brokerage recommended the stock to buy at a market price of Rs 1,189, but it is now trading at Rs 1,063.65.

According to the brokerage “The impact of COVID-19 on asset quality appears to be controlled as asset quality ratios witnessed an improvement, with GNPA/NNPA at 2.8%/0.8% as of 2QFY22. Collection efficiency improved to 98% in Sep’21. We expect this to gain further traction. The restructuring book remains high at ~3.6% v/s peers. However, healthy PCR (~72%), coupled with a provision buffer of 1.4% of loans, provides comfort. We remain watchful of asset quality as slippages could remain elevated in the near term and moderate post FY22. We estimate credit cost to remain at 2.8%/2.0% in FY22E/FY23E and moderate to 1.8% in FY24E.” The brokerage has said “IndusInd Bank had rolled out its ‘Planning Cycle 5′ (CY20-23), wherein it would focus on fortifying its liabilities, scaling up its key focus businesses, and investing in new growth engines. It expects the loan book to grow at 15-18% over FY2-223E (unsecured retail at less than 5%), with the CASA ratio in excess of 40% by FY23E. We estimate the loan book to grow 17% over FY21-24E.”

According to Motilal Oswal, “the management has maintained its loan growth and credit cost guidance as given during the 2QFY22 results. It expects loan growth to be 16-18% and credit cost of 160-190bp, plus an additional 50bp for Vodafone. Thus, the total credit cost guidance stands at 240bp. We estimate a loan growth CAGR of 17% over FY21-24E / credit cost of 2.8% for FY22E and moderate it to 2.0%/1.8% for FY23E/FY24E.”

Motilal Oswal in its research report said “The stock could witness some pressure due to adverse media articles and asset quality stress reported by some other MFI lenders. Nevertheless, we expect the impact to be controlled. We expect RoA/RoE of 1.8%/15.1% in FY23E. We maintain BUY, with unchanged TP of INR1,400 (1.9x 1HFY24E ABV).”

Disclaimer

Disclaimer

The above stocks have been picked from the brokerage report of Motilal Oswal. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution. Greynium Information Technologies, the author, and the brokerage house are not liable for any losses caused as a result of decisions based on the article.



[ad_2]

CLICK HERE TO APPLY

IndusInd Bank shares tank after report of loan evergreening allegation at unit, BFSI News, ET BFSI

[ad_1]

Read More/Less


BENGALURU – Shares of IndusInd Bank slid as much as 11.45% on Monday after a report said whistleblowers had alleged loan evergreening at the private sector lender’s micro finance arm.

On Friday, the Economic Times reported that whistleblowers had alerted the Reserve Bank of India (RBI) and the IndusInd board that Bharat Financial Inclusion (BFIL) had evergreened some loans – a practice where new loans are given to stressed borrowers to enable them to repay existing loans.

IndusInd denied the allegation in an exchange filing on Nov. 6 and said the report was “grossly inaccurate and baseless”.

However, it said nearly 84,000 loans were disbursed in May without customer consent due to a technical glitch and that the issue was rectified expeditiously.

IndusInd did not immediately respond to a Reuters request for comment.

On Monday, shares of the private sector lender were the top percentage losers on the Nifty private bank index and on track for their worst session since April 2020.

Due to pandemic-related restrictions, some loans had to be disbursed via cash at BFIL, and as of September-end, only 26,073 clients out of 84,000 were active with loan outstanding at 340 million rupees ($4.58 million), IndusInd said.

In multiple emails to the RBI and the IndusInd board in October, a whistleblower group that included BFIL officials alleged that the unit had evergreened loans, inflated revenues and under-reported non-performing assets, the report said.

The report also cited two people familiar with the developments saying there was a separate whistleblower complaint from an outsider on Oct. 14 that suggestions to set up risk management and audit committees for BFIL were ignored.

In its exchange filing, IndusInd said an independent review had been initiated by the bank to see if there was any process lapse or accounting failure at BFIL.

($1 = 74.1900 Indian rupees)

(Reporting by Chandini Monnappa in Bengaluru; Editing by Subhranshu Sahu)



[ad_2]

CLICK HERE TO APPLY

Rupee surges 27 paise to 74.19 against US dollar in early trade

[ad_1]

Read More/Less


The rupee surged 27 paise to 74.19 against the US dollar in opening trade on Monday supported by dovish central banks.

At the interbank foreign exchange, the rupee opened strong at 74.25 against the dollar and gained further ground to 74.19 in early deals, a rise of 27 paise over its previous close.

On Thursday, the rupee had settled at 74.46 against the US dollar.

The forex market was closed on Friday for ‘Diwali Balipratipada’.

The Indian Rupee opened stronger this Monday supported by dovish central banks, Reliance Securities said in a research note.

Fed’s taper announcement

Fed Chair Jerome Powell said he was in no rush to hike borrowing costs, as there was still ground to cover to reach maximum employment. The central bank did announce a $15 billion monthly tapering of its $120 billion in monthly asset purchases.

Additionally, flows into the market could also lend support. However, the Reserve Bank of India’s presence could cap the appreciation bias, the note said.

Meanwhile, the dollar index, which gauges the greenback’s strength against a basket of six currencies, fell 0.01 per cent to 94.31.

Global oil benchmark Brent crude futures rose 1.02 per cent to $83.58 per barrel.

On the domestic equity market front, BSE Sensex was trading 221.26 points or 0.37 per cent lower at 59,846.36, while the broader NSE Nifty declined 56.75 points or 0.32 per cent to 17,860.05.

Foreign institutional investors were net sellers in the capital market on Thursday as they offloaded shares worth ₹328.11 crore, as per exchange data.

[ad_2]

CLICK HERE TO APPLY

Banks Board Bureau to soon start appointment process for MD, DMDs at NaBFID, BFSI News, ET BFSI

[ad_1]

Read More/Less


The government had recently said that beginning October 2021, all pens would be taxed at 18%.

The finance ministry will soon start the process for the appointment of managing director (MD) and deputy managing directors (DMDs) of the newly set up Rs 20,000 crore development finance institution NaBFID, to catalyse investment in the fund-starved infrastructure sector.

Last month, the government appointed veteran banker KV Kamath as the chairperson of the National Bank for Financing Infrastructure and Development (NaBFID) for three years.

The finance ministry will soon intimate the Banks Board Bureau (BBB) about the appointment of MD and DMDs of NaBFID.The Bureau will issue advertisements and undertake a selection process, sources said.

The BBB is the headhunter for state-owned banks and financial institutions. The MD, DMDs and whole-time directors would not hold office after attaining the age of 65 years and 62 years respectively.

As per the National Bank for Financing Infrastructure and Development (NaBFID) Act, 2021, the institution would have one MD and not more than three DMDs.

The national infra bank

The government has committed a Rs 5,000-crore grant over and above Rs 20,000 crore equity capital. The central government will provide grants by the end of the first financial year. The government will also provide a guarantee at a concessional rate of up to 0.1 per cent for borrowing from multilateral institutions, sovereign wealth funds, and other foreign funds.

The development finance institution (DFI) has been established as a statutory body to address market failures that stem from the long-term, low margin and risky nature of infrastructure financing.

The DFI, therefore, has both developmental and financial objectives. To begin with, the institution will be 100 per cent government-owned.

It will help fund about 7,000 infra projects under the National Infrastructure Pipeline (NIP) which envisages an investment of Rs 111 lakh crore by 2024-25.

The DFI will remain outside the purview of CAG, CVC and CBI, a move aimed at enabling faster decision-making. The government expects the DFI to leverage this fund to raise up to Rs 3 lakh crore in the next few years.

Development finance institutions

During the pre-liberalised era, India had DFIs which were primarily engaged in the development of the industry. ICICI and IDBI, in their previous avatars, were DFIs. Even the country’s oldest financial institution IFCI Ltd functioned as a DFI.

In India, the first DFI was operationalised in 1948, with the setting up of the Industrial Finance Corporation of India (IFCI).

Subsequently, the Industrial Credit and Investment Corporation of India (ICICI) was set up with the backing of the World Bank in 1955. The Industrial Development Bank of India (IDBI) came into existence in 1964, to promote long-term financing for infrastructure projects and industry.



[ad_2]

CLICK HERE TO APPLY

Buy This Company Stock With 24% Return In 1 Year: ICICI Securities

[ad_1]

Read More/Less


Target Price

The current market price of Graphite India (GIL) is Rs. 525. ICICI Securities has set a target price of Rs. 650 for the stock that is expected to give 24% returns in a 1 year period to investors. So investors can consider this stock to buy now.

Stock expectation
Current market price Rs. 525
Target price Rs. 650
1 year returns 24.00%

Company performance

Company performance

Graphite India reports a consolidated capacity utilization of 81% compared to 60% in Q2FY21 and 75% in Q1FY22. ICICI Securities estimate for the company was 78%. the company’s consolidated topline for the quarter stood at Rs. 692 crore, up 43% YoY and 13% QoQ. The brokerage firm expected it to be Rs. 712 crore.

Graphite India reports a consolidated net profit during the last quarter at Rs. 128 crore, which was down 15% QoQ. On the other hand, they reported a consolidated EBITDA at Rs. 109 crore, which was down 23% QoQ. However, their consolidated EBITDA margin came in at 15.8% compared to 23.1% in Q1FY22

ICICI Securities' stand on the stock

ICICI Securities’ stand on the stock

The brokerage firm in their report said, “GIL’s share price has grown by ~3x over the last 12 months (from ~ Rs. 176 on November 2020 to ~ Rs. 525 levels in November 2021). We maintain our BUY rating on the stock. We value GIL at Rs. 650, 6.5x FY23E EV/EBITDA. The performance set to improve, going forward.” Hence, keeping a target of Rs. 650, investors can buy this stock, as recommended by ICICI Securities.

About Graphite India (GIL)

About Graphite India (GIL)

ICICI Securities has said that Graphite India (GIL) is the largest Indian producer of graphite electrodes by total capacity. The company’s manufacturing capacity of 98000 tonnes PA is spread over 3 plants at Durgapur & Nashik in India & Nuremberg in Germany. “GIL manufactures a full range of graphite electrodes, it stays focused on the higher-margin, large diameter, ultra-high power (UHP) electrodes. GIL has over 40 years of technical expertise in the industry”, the firm informed.

Disclaimer

Disclaimer

The above stock has been picked from the brokerage report of ICICI Securities. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution. Greynium Information Technologies, the author, and the brokerage house are not liable for any losses caused as a result of decisions based on the article.



[ad_2]

CLICK HERE TO APPLY

Bankers must do proper due diligence before joining corporates, says Amarjit Chopra, BFSI News, ET BFSI

[ad_1]

Read More/Less


The arrest of Former SBI Chair Pratip Chaudhuri sends a clear message to the bankers that they must lot of due diligence of companies particularly NBFCs whose boards they are joining post-retirement, says Amarjit Chopra, who has held several directorships in public sector banks, and was also a former president at the Institute of Chartered Accountants of India (ICAI).

“Firstly credentials of promoters and secondly past relationship of bankers in their various capacities in banks with such companies need to be kept in mind. Not following this gives rise to unnecessary suspicion and speculations,” Chopra said, as he reflected on the arrest of Chaudhari’s arrest by Enforcement Directorate earlier this month in connection with a loan scam case. Below are edited excerpts from the interaction:

Q: What is your initial impression on the arrest of Ex SBI Chair Pratip Chaudhuri in a loan scam case?

Amarjit Chopra: It is extremely unfortunate that a person of his stature with an impeccable track record has been arrested without an appreciation of facts. His reputation has been tarnished for no reason. And to me his arrest is a big setback to the morale of banking personnel particularly when the economy needs a boost in credit expansion

Q: SBI Chair Dinesh Kumar Khara has said Chaudhuri has not been given an opportunity to be heard, Also, many bankers have described this as high handedness by enforcement agencies/ police. What is your view?

Amarjit Chopra: From the reports it appears that Pratip Chaudhuri was not given any opportunity to be heard before his arrest. Prima facie his arrest reflects high handedness on the part of enforcement agencies and police.

One needs to understand the facts to appreciate the wrong done to Pratip Chaudhuri. The promoters of the Jaisalmer hotel project, Garh Rajwada, approached SBI for a loan to construct a hotel. The loan of Rs 24 crore would have been sanctioned following a process. Going by the amount and the fact that the bank involved was SBI the case would not have gone to the level of MD/Chairman of that period..

Loan proposal along with technical and financial feasibility report of the project, valuation report of the land and other documents etc would have been obtained and appraised before any recommendation for sanction of loan by any official/ committee.

The loan was disbursed in the year 2008. The borrower did not complete the project. A key promoter passed away in 2010. Needless to say that as per banking norms opportunities would have been given to the borrower to settle the amount or to complete the project which the promoters failed to do. Consequently, the loan was classified as NPA.

Going by my experience in all such cases the banks do try to persuade the borrowers in such cases to settle the matter before resorting to other measures. This case would have been no exception to the same. In this case as the promoters neither settled the account nor completed the project the bank was left with no alternative but to follow the process of selling the NPA to ARC Alchemist in 2014 and ARC stepped into the shoes of the lender bank. This was done four years after the death of the key promoter.

Q: What according to you could have prompted the enforcement agencies to arrest Chaudhuri in the first place?

Amarjit Chopra:

It may be interesting to note that Pratip Chaudhuri became Chairman in April 2011 i.e. after sanction and disbursal of loan and rather after the account had turned NPA and retired in September 2013 i.e. before the sale of the asset to ARC Alchemist..

Pratip Chaudhuri joined Alchemist Board in October 2014 after completing a mandatory cooling period of one year after his retirement from SBI. Alchemist had stepped into the shoes of the lender by acquiring the asset. To my mind, ARC would have tried to negotiate it with borrowers but later on sold the asset to another party, an NBFC in 2017.

So far as I understand the process clearly, the bank before selling the asset to ARC Alchemist would have obtained a valuation report and would have advertised the sale in newspapers. In case promoters had any objection they should have filed the objection at that time rather than filing any complaint later after the sale of the asset. They had an opportunity to settle the account presale with the bank and postsale with ARC. So, there appears to be no justification in their filing a protest petition with Chief Judicial Magistrate later and alleging sale of the asset at lower price.

It is surprising that the court has taken cognisance of a complaint by a defaulter who failed to execute the project and later on refused to settle the account. Enforcement agencies having taken cognisance of such complaints would only encourage more financial indiscipline on the part of defaulters..

It is crystal clear that Pratip Chaudhuri was not even Chairman of SBI when the sale to ARC happened. So the allegation against him cannot be in his capacity as a banker. A protest petition has been filed against ARC Alchemist and all of its directors without making SBI a party. It is shocking that Alok Dhir, the promoter of ARC Alchemist, has evaded arrest. It may not be wrong to presume that the action that Chaudhuri faces is not because of being Chairman of SBI. Rather he faces this action being on the Board of ARC Alchemist as this company was involved in the purchase and sale of the asset.

Q: Does Enforcement Directorate seem to have jumped the gun in this case?

Amarjit Chopra: Probably yes! The Supreme Court in a recent judgement in case of Ravindranatha Bajpe versus Mangalore Special Economic Zone Ltd and others has clearly held that no vicarious liability would come on any director for any criminal offences of the company till the time it is proved that he had consented or had knowledge of a fraud.

In the given case based on protest petition even if enforcement agencies/police had to proceed, the same could have been based on investigations into conduct of various parties including the borrowers and the findings thereof. An action like arrest cannot be based upon surmises and conjectures..

Q: What does Chaudhuri’s arrest imply for the banking industry?

Amarjit Chopra: In recent years after the arrest of certain top functionaries of Bank of Maharashtra, IDBI etc bankers had become risk-averse and the same affected credit expansion adversely. The slowdown in credit expansion also resulted in economic sluggishness in the country.

It may be worthwhile to point out that Bank of Maharashtra officials were later exonerated of all charges but the damage was done to the morale of banking staff.

A couple of days back the government issued instructions to ensure that enforcement agencies need to distinguish between genuine banking business decisions and actions taken with an intent to defraud. It was done primarily with a view to infuse confidence in bankers that a protection cover is being provided to them for their genuine business decisions.

But this one case has nullified the impact of those instructions. It is despite the fact that apparently, this action against Chaudhuri has nothing to do with his role as a banker as stated earlier.

In my opinion, going by human psychology it would certainly affect credit expansion as well as cleaning up of the balance sheets of banks particularly through sales of bad loans to ARCs. Here I will certainly like to add that all these years the role of various ARCs has not been free from controversy and needs to be looked into. The government and RBI would do well to constitute a group to suggest some measures to improve the functioning of ARCs..

Q: What is the signal reflected by the enforcement agencies here?

Amarjit Chopra: It is difficult to answer. But one message is loud and clear that top functionaries in banks need to do a lot of due diligence of companies, particularly NBFCs whose boards they are joining post-retirement. Firstly credentials of promoters and secondly past relationship of bankers in their various capacities in banks with such companies need to be kept in mind. Not following this gives rise to unnecessary suspicion and speculations.

Motives can be imputed and at times certain genuine business decisions may be looked at with a different mindset by public and enforcement agencies. Keeping oneself engaged post-retirement is fine but joining the boards of companies with which one has dealt with in various capacities as banker may not be a healthy trend..

Unfortunately in the recent past, there has been an increasing trend amongst bankers and bureaucrats joining the boards of such companies that they dealt with as senior functionaries. One may be honest but it is equally important to appear as honest.

It may not be an exaggeration to say that enforcement agencies in the given case probably acted upon the surmise that Chaudhuri happens to be a director on the board of Alchemist and earlier he and the company had a business relationship. So, better avoid such conflicted appearing positions.

Q: Do you have any suggestions for the government/ RBI?

Amarjit Chopra: The government and RBI would do well to review the extent of mandatory cooling period that officials of banks and bureaucrats may have to observe post-retirement before taking up an assignment with private entities, particularly whose files they have dealt with in the last three years of their official position.



[ad_2]

CLICK HERE TO APPLY

5 Multibagger Penny Stocks Of 2021 That Delivered Up To 1800% Return So Far

[ad_1]

Read More/Less


1. JITF Infralogistics:

The company commands a market cap of Rs. 575 crore and has recorded a surge of 3073 percent in the last one year. While YTD returns have also been phenomenal of over 1700 percent. The exorbitant price rise in the stock is being attributed to low liquidity in the stock. The other concern with the company is institutional holding in the company is by investors who were recently under the scanner owing to investment in Adani Group firms.

In the previous quarter ending June 2021, the company posted a net loss of Rs. 0.04 crore. The company’s stock was locked in upper circuit from August to October 2021.

The company works in the area of water, wastewater and solid waste management, logistics and transportation equipment fabrication.

2.	ANG Lifesciences:

2. ANG Lifesciences:

The pharma company has returned a staggering 2896 percent return in the last 1-year, while YTD return have been over 1812%. After acquiring 2 formulation manufacturing facilities, the company’s stock is on the run. Also, the company declared a bonus in the ratio of 1:1 which is also providing a stock the current fillip as the investors lap up stocks for which record date has been declared.

Incorporated in the year 2008, the company has its focus primarily on Dry Powder Injectables (SVP). ANG Lifescience is committed to Quality products and services that address the prevention , diagnosis and treatment of diseases, thus enhancing people’s health and quality of life .

3. Orchid Pharma:

3. Orchid Pharma:

The pharma company over a 1-year period has risen 1890 percent and last quotes at a price of Rs. 413 per share on the NSE.

The was relisted in 2020 at a price of Rs. 18 and since then till April of this year gave an over 14000 percent return. Limited stock or free float is the main reason spurring the stock price of Orchid.

Established in 1992 as an export-oriented unit (EOU), Orchid Pharma Ltd. (Orchid) is a vertically integrated company spanning the entire pharmaceutical value chain from discovery to delivery with established credentials in research, manufacturing and marketing.

Orchid Pharma last commands an market cap of Rs. 1685 crore.The stock’s 52-week high price is Rs. 2654.

4.	3i Infotech:

4. 3i Infotech:

The computer software firm was relisted and since then has been in high demand after the company’s debt restructuring plan. As a result of the new plan, the company’s capital base has been brought down. The stock is expected to see further upside. The company is now a debt free enterprise.

Over the year gone by, shares of the company have gained 1,468%.

5.	Authum Investment

5. Authum Investment

Authum Investment & Infrastructure is a registered NBFC, carrying on the business of investment in shares & securities and also, financing activities. The company has been in news after it came out as the successful bidder for the acquisition of Reliance Commercial Finance (RCF) and Reliance Home Finance. Authum will pay around Rs 22 bn for RCF and close to Rs 29 bn for Reliance Home Finance.

Stocks YTD return 1 year return Sector
ANG Lifesciences 1812% 2896% Pharma
Authum Investment 714% 940% NBFC
JITF Infralogistics >1700% 3073% Diversified
Orchid Pharma 1890% Pharma
3i Infotech 715.5% 1683% Software

Disclaimer:

Disclaimer:

The story above just highlights the mind boggling returns these penny stocks managed to gave, nonetheless it is not a recommendation to buy in these shares as these stocks in particular are highly risky and past returns are no metric to decide on an investment.

GoodReturns.in



[ad_2]

CLICK HERE TO APPLY

Reserve Bank of India – Press Releases

[ad_1]

Read More/Less



(Amount in ₹ crore, Rate in Per cent)

  Volume
(One Leg)
Weighted
Average Rate
Range
A. Overnight Segment (I+II+III+IV) 2,862.02 1.66 0.01-3.50
     I. Call Money 740.37 3.10 2.70-3.45
     II. Triparty Repo 2,121.65 1.16 0.01-3.50
     III. Market Repo 0.00  
     IV. Repo in Corporate Bond 0.00  
B. Term Segment      
     I. Notice Money** 10,617.92 3.43 2.00-3.65
     II. Term Money@@ 225.00 3.25-3.99
     III. Triparty Repo 334,234.25 3.50 3.00-3.62
     IV. Market Repo 116,764.15 3.44 1.00-3.70
     V. Repo in Corporate Bond 198.00 3.60 3.60-3.60
  Auction Date Tenor (Days) Maturity Date Amount Current Rate /
Cut off Rate
C. Liquidity Adjustment Facility (LAF) & Marginal Standing Facility (MSF)
I. Today’s Operations
1. Fixed Rate          
     (i) Repo          
    (ii) Reverse Repo Wed, 03/11/2021 5 Mon, 08/11/2021 160,485.00 3.35
    (iii) Special Reverse Repo~ Wed, 03/11/2021 15 Thu, 18/11/2021 1,158.00 3.75
    (iv) Special Reverse Repoψ Wed, 03/11/2021 15 Thu, 18/11/2021 291.00 3.75
2. Variable Rate&          
  (I) Main Operation          
     (a) Reverse Repo Wed, 03/11/2021 15 Thu, 18/11/2021 434,492.00 3.99
  (II) Fine Tuning Operations          
     (a) Repo          
     (b) Reverse Repo          
           
3. MSF Wed, 03/11/2021 5 Mon, 08/11/2021 244.00 4.25
4. Special Long-Term Repo Operations (SLTRO) for Small Finance Banks (SFBs)£          
5. Net liquidity injected from today’s operations
[injection (+)/absorption (-)]*
      -596,182.00  
II. Outstanding Operations
1. Fixed Rate          
    (i) Repo          
    (ii) Reverse Repo          
    (iii) Special Reverse Repo~          
    (iv) Special Reverse Repoψ          
2. Variable Rate&          
  (I) Main Operation          
     (a) Reverse Repo          
  (II) Fine Tuning Operations          
     (a) Repo          
     (b) Reverse Repo Tue, 02/11/2021 7 Tue, 09/11/2021 150,015.00 3.95
  Tue, 02/11/2021 28 Tue, 30/11/2021 50,007.00 3.97
3. MSF          
4. Long-Term Repo Operations# Mon, 17/02/2020 1095 Thu, 16/02/2023 499.00 5.15
  Mon, 02/03/2020 1094 Wed, 01/03/2023 253.00 5.15
  Mon, 09/03/2020 1093 Tue, 07/03/2023 484.00 5.15
  Wed, 18/03/2020 1094 Fri, 17/03/2023 294.00 5.15
5. Targeted Long Term Repo Operations^ Fri, 27/03/2020 1092 Fri, 24/03/2023 12,236.00 4.40
  Fri, 03/04/2020 1095 Mon, 03/04/2023 16,925.00 4.40
  Thu, 09/04/2020 1093 Fri, 07/04/2023 18,042.00 4.40
  Fri, 17/04/2020 1091 Thu, 13/04/2023 20,399.00 4.40
6. Targeted Long Term Repo Operations 2.0^ Thu, 23/04/2020 1093 Fri, 21/04/2023 7,950.00 4.40
7. On Tap Targeted Long Term Repo Operations Mon, 22/03/2021 1095 Thu, 21/03/2024 5,000.00 4.00
  Mon, 14/06/2021 1096 Fri, 14/06/2024 320.00 4.00
  Mon, 30/08/2021 1095 Thu, 29/08/2024 50.00 4.00
  Mon, 13/09/2021 1095 Thu, 12/09/2024 200.00 4.00
  Mon, 27/09/2021 1095 Thu, 26/09/2024 600.00 4.00
  Mon, 04/10/2021 1095 Thu, 03/10/2024 350.00 4.00
8. Special Long-Term Repo Operations (SLTRO) for Small Finance Banks (SFBs)£ Mon, 17/05/2021 1095 Thu, 16/05/2024 400.00 4.00
Tue, 15/06/2021 1095 Fri, 14/06/2024 490.00 4.00
Thu, 15/07/2021 1093 Fri, 12/07/2024 750.00 4.00
Tue, 17/08/2021 1095 Fri, 16/08/2024 250.00 4.00
Wed, 15/09/2021 1094 Fri, 13/09/2024 150.00 4.00
D. Standing Liquidity Facility (SLF) Availed from RBI$       21,695.80  
E. Net liquidity injected from outstanding operations [injection (+)/absorption (-)]*     -92,684.2  
F. Net liquidity injected (outstanding including today’s operations) [injection (+)/absorption (-)]*     -688,866.2  
G. Cash Reserves Position of Scheduled Commercial Banks
     (i) Cash balances with RBI as on 03/11/2021 711,756.61  
     (ii) Average daily cash reserve requirement for the fortnight ending 05/11/2021 636,507.00  
H. Government of India Surplus Cash Balance Reckoned for Auction as on¥ 03/11/2021 0.00  
I. Net durable liquidity [surplus (+)/deficit (-)] as on 22/10/2021 1,179,109.00  
@ Based on Reserve Bank of India (RBI) / Clearing Corporation of India Limited (CCIL).
– Not Applicable / No Transaction.
** Relates to uncollateralized transactions of 2 to 14 days tenor.
@@ Relates to uncollateralized transactions of 15 days to one year tenor.
$ Includes refinance facilities extended by RBI.
& As per the Press Release No. 2019-2020/1900 dated February 06, 2020.
* Net liquidity is calculated as Repo+MSF+SLF-Reverse Repo.
# As per the Press Release No. 2020-2021/287 dated September 04, 2020.
^ As per the Press Release No. 2020-2021/605 dated November 06, 2020.
As per the Press Release No. 2020-2021/520 dated October 21, 2020, Press Release No. 2020-2021/763 dated December 11, 2020, Press Release No. 2020-2021/1057 dated February 05, 2021 and Press Release No. 2021-2022/695 dated August 13, 2021.
¥ As per the Press Release No. 2014-2015/1971 dated March 19, 2015.
£  As per the Press Release No. 2021-2022/181 dated May 07, 2021 and Press Release No. 2021-2022/1023 dated October 11, 2021.
~ As per the Press Release No. 2021-2022/177 dated May 07, 2021.
ψ As per the Press Release No. 2021-2022/323 dated June 04, 2021.
Ajit Prasad
Director   
Press Release: 2021-2022/1151

[ad_2]

CLICK HERE TO APPLY

1 113 114 115 116 117 16,278